Farxiga HSA/FSA Eligibility and Submission: How to Pay Less for Dapagliflozin in 2026

Is Farxiga HSA/FSA Eligible?

Farxiga is HSA- and FSA-eligible because it is a prescription medication. The IRS defines eligible medical expenses in IRS Publication 502, which explicitly includes the cost of prescription drugs. Any medication that legally requires a prescription from a licensed provider qualifies. Dapagliflozin 5 mg and 10 mg tablets require a prescription in the United States under FDA approval, so every fill is reimbursable from either account type.

How the IRS Rule Works

The IRS treats Health Savings Accounts and Flexible Spending Accounts similarly for prescription drugs. IRS Publication 502 (2024 edition) states: "You can include in medical expenses amounts you pay for prescription medicines or drugs. A prescribed drug is one that requires a prescription by a doctor for its use by an individual."

Dapagliflozin satisfies both criteria. Your pharmacist prints a Rx number on every receipt, which serves as proof of eligibility if your plan administrator requests documentation.

What "Eligible" Actually Means for Your Wallet

Eligible status means you can pay your pharmacy directly with your HSA debit card or FSA card, or pay out-of-pocket and submit for reimbursement later. Both routes work. The net effect is that you purchase Farxiga with pre-tax dollars, reducing your effective cost by your marginal tax rate, typically 22 to 32% for most employed adults.

How to Submit an HSA or FSA Claim for Farxiga

Submission is straightforward. Collect your itemized pharmacy receipt or your insurer's Explanation of Benefits (EOB), log into your plan administrator's portal, and upload the document. Most administrators process claims within 3 to 5 business days. The FDA's Orange Book entry for dapagliflozin confirms its prescription status if a plan administrator ever questions eligibility.

What Documentation You Need

Your receipt must show four things: the patient name, the drug name (dapagliflozin or Farxiga), the dispensing date, and the amount paid. Most retail pharmacy receipts include all four automatically. If you use a mail-order pharmacy, the shipping invoice typically contains the same details.

Using Your HSA/FSA Debit Card at the Pharmacy

If you swipe your HSA or FSA card directly, no claim submission is required. The card's IIAS (Inventory Information Approval System) automatically flags prescription drugs as eligible at point-of-sale. Keep your receipt anyway, the IRS can audit HSA withdrawals up to six years after the tax year in question, per IRS Publication 969.

Co-Pay Cards and HSA/FSA Interaction

One critical exception: you cannot use HSA or FSA funds to cover the same expense already paid by a manufacturer co-pay card. Double-dipping violates IRS rules. If AstraZeneca's co-pay card covers your entire cost at the pharmacy, your out-of-pocket expense is zero and there is nothing to reimburse from your HSA or FSA. If you pay a residual amount after the co-pay card applies, that residual is HSA/FSA eligible.

AstraZeneca Co-Pay Card: How to Get Farxiga for as Low as $0/Month

AstraZeneca offers a co-pay savings program for commercially insured patients. Eligible patients may pay as little as $0 per month, up to an annual savings cap set by AstraZeneca (caps change each calendar year, verify at AstraZeneca's official savings page before enrolling). The program is not available to patients using Medicare, Medicaid, or any other federal or state payer.

Eligibility Requirements

To qualify for the co-pay card, you must:

• Have commercial (private) insurance that covers Farxiga.
• Be a resident of the United States or Puerto Rico.
• Not be enrolled in Medicare Part D, Medicaid, or TRICARE.
• Have a valid prescription for an FDA-approved indication.

Dapagliflozin's three approved indications, type 2 diabetes, heart failure with reduced ejection fraction, and chronic kidney disease, are each supported by large outcomes trials. DECLARE-TIMI 58 (N=17,160) demonstrated a statistically significant 17% reduction in hospitalization for heart failure with dapagliflozin 10 mg versus placebo (HR 0.83, 95% CI 0.73 to 0.95, P<0.005) [1]. DAPA-HF (N=4,744) showed a 26% reduction in the composite of worsening heart failure or cardiovascular death (HR 0.74, 95% CI 0.65 to 0.85, P<0.001) [2]. DAPA-CKD (N=4,304) reported a 39% reduction in sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) [3]. These are the clinical foundations upon which the FDA approved each indication, and each approved indication makes the prescription HSA/FSA eligible and co-pay card eligible.

How to Enroll

1. Ask your prescriber to confirm your FDA-approved indication on the prescription.
2. Visit AstraZeneca's savings site or ask your pharmacist to enroll you at the point of sale.
3. Present your co-pay card (physical or digital) at the pharmacy.
4. Save your receipt showing any residual out-of-pocket cost for potential HSA/FSA reimbursement.

AZ&Me Prescription Savings Program: Free Farxiga for Uninsured or Underinsured Patients

AstraZeneca's patient assistance program, AZ&Me, provides free Farxiga to patients who meet income and insurance criteria. As of 2026, patients without prescription drug coverage or with limited coverage may qualify if their household income falls below a threshold set by AstraZeneca (thresholds are updated annually, confirm current limits at the AZ&Me program page).

Who Should Apply

AZ&Me is designed for patients who:

• Have no prescription drug insurance, or whose insurance does not cover Farxiga.
• Cannot afford their medication even with a co-pay card.
• Do not qualify for Medicare Part D Low Income Subsidy (Extra Help).

The FDA's patient assistance guidance notes that manufacturer programs are one of several mechanisms patients can use to reduce prescription costs. The National Institutes of Health MedlinePlus resource on drug costs similarly lists manufacturer assistance as a primary strategy.

How to Apply

Applications go through AstraZeneca directly. Your prescriber's office may submit on your behalf, which speeds approval. Processing typically takes 2 to 4 weeks. Once approved, medication ships to your prescriber's office or directly to your home, depending on program logistics.

GoodRx, Mark Cuban Cost Plus Drugs, and Other Discount Channels

Patients without insurance or whose insurance tier places Farxiga at a high co-pay have additional options beyond manufacturer programs.

GoodRx and Coupon Aggregators

GoodRx and similar coupon aggregators negotiate discounted cash prices with pharmacy benefit managers. Dapagliflozin 10 mg, 30 tablets, lists at $640, $680 retail at major chains in 2026. GoodRx coupons may bring this to $500, $580 depending on the pharmacy and zip code. These prices fluctuate weekly.

One important tax note: GoodRx payments are not insurance payments. You pay cash, so the full amount may be submitted for HSA or FSA reimbursement, as long as you have a valid prescription receipt showing the drug name and date. IRS Publication 502 does not distinguish between payments to insurance plans and cash payments to pharmacies for eligible prescriptions.

Mark Cuban Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) carries generic dapagliflozin. Generic dapagliflozin received FDA approval, and Cost Plus may list it significantly below brand Farxiga pricing. Generic dapagliflozin is bioequivalent to Farxiga per the FDA Orange Book and is HSA/FSA eligible under the same IRS rule. If your prescriber writes for dapagliflozin (generic) rather than brand Farxiga, a Cost Plus purchase may represent the lowest total cost for a cash-pay patient.

Pharmacy Membership Programs

Several national chains, Costco, Walmart, and Amazon Pharmacy, offer internal membership pricing on generic drugs. Generic dapagliflozin qualifies. These purchases are also HSA/FSA reimbursable with a valid receipt.

Medicare Part D and Farxiga Costs in 2026

Medicare Part D underwent significant structural changes under the Inflation Reduction Act. Starting January 1, 2025, Medicare Part D out-of-pocket spending is capped at $2,000 per year for covered drugs. Farxiga is covered on most Part D formularies, typically in Tier 3 or Tier 4.

The $2,000 Annual Cap

The $2,000 cap means that once a beneficiary spends $2,000 on covered Part D drugs in a calendar year, they pay $0 for the remainder of the year. For patients who take Farxiga plus other expensive medications, this cap may be reached mid-year. The Centers for Medicare and Medicaid Services summarizes these changes and recommends patients compare Part D plans annually using Medicare's Plan Finder tool.

HSA Compatibility With Medicare

Patients enrolled in Medicare cannot contribute to an HSA. They may still spend existing HSA balances on Farxiga co-pays under Medicare Part D, because Part D cost-sharing qualifies as a medical expense under IRS Publication 969. This is a commonly missed savings opportunity for beneficiaries who accumulated HSA balances before Medicare enrollment.

Manufacturer co-pay cards, however, are prohibited for Medicare Part D enrollees under federal anti-kickback statute guidance. OIG Advisory Opinion No. 02-01 and subsequent guidance establish that manufacturer subsidies cannot offset federal program cost-sharing.

Clinical Evidence Supporting Farxiga's Three FDA Indications

Understanding why a prescriber chose Farxiga helps patients advocate for coverage and manage prior authorization. Payers are less likely to deny coverage when the clinical rationale aligns with FDA-approved labeling and major guideline recommendations.

Type 2 Diabetes

Dapagliflozin 10 mg lowers HbA1c by approximately 0.8 to 1.2% from baseline in adults with type 2 diabetes, based on Phase 3 registration trials submitted to the FDA [4]. The American Diabetes Association Standards of Care 2024 recommend SGLT2 inhibitors as preferred add-on agents in patients with established cardiovascular disease, heart failure, or CKD, making dapagliflozin a guideline-preferred choice across multiple comorbidity profiles.

The ADA statement reads in part: "In patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended to reduce the risk of major adverse cardiovascular events and/or heart failure hospitalization." [4]

Heart Failure

DAPA-HF enrolled 4,744 patients with HFrEF (EF <40%) regardless of diabetes status. At 18.2 months median follow-up, dapagliflozin 10 mg once daily reduced the primary composite endpoint (worsening heart failure or cardiovascular death) by 26% versus placebo [2]. The 2022 AHA/ACC/HFSA Heart Failure Guideline gives SGLT2 inhibitors a Class I, Level A recommendation for patients with HFrEF, stating they "are recommended to reduce hospitalizations for HF and cardiovascular mortality." [5]

Chronic Kidney Disease

DAPA-CKD enrolled 4,304 patients with CKD stages 2 to 4 (eGFR 25 to 75 mL/min/1.73 m²) and urine albumin-to-creatinine ratio 200 to 5,000 mg/g, with or without type 2 diabetes. Dapagliflozin 10 mg reduced the composite of sustained eGFR decline, ESKD, or renal/cardiovascular death by 39% (HR 0.61, P<0.001) [3]. The trial was stopped early for efficacy. KDIGO 2024 guidelines now recommend SGLT2 inhibitors for patients with CKD and eGFR >20 mL/min/1.73 m², with dapagliflozin among the most studied agents.

Prior Authorization: What to Expect and How to Speed Approval

Most commercial plans and Medicare Part D require prior authorization for Farxiga. The PA process typically asks your prescriber to document your diagnosis, prior treatment history (often metformin for T2D, or ACE inhibitor/ARB for HF or CKD), and labs confirming the indication.

Standard PA Criteria by Indication

Type 2 diabetes: Most plans require evidence of inadequate glycemic control on metformin or metformin contraindication, plus HbA1c above a threshold (often >7.5% or >8.0%).

Heart failure: Plans typically accept a documented diagnosis of HFrEF with EF <40% and a note that the patient is on maximally tolerated background therapy (beta-blocker plus ACE inhibitor/ARB/ARNI).

CKD: Plans often require a recent eGFR lab (25 to 75 mL/min/1.73 m²) and urine albumin-to-creatinine ratio >200 mg/g, consistent with DAPA-CKD enrollment criteria [3].

Step Therapy Overrides

Some plans require a step-through trial of a lower-tier SGLT2 inhibitor (most often empagliflozin, which is on the same formulary tier at many PBMs) before approving Farxiga. If your prescriber has a clinical reason to prefer dapagliflozin specifically, for instance, its CKD indication extends to patients without diabetes, which not all SGLT2 inhibitors share, that rationale can support a medical necessity override. The FDA label for Farxiga documents all three indications explicitly, which your prescriber can attach to the PA appeal.

Appeal Rights

If your PA is denied, federal law requires your insurer to provide an internal appeal within 30 days (or 72 hours for urgent cases) under the ACA's internal appeals and external review rules. External review by an independent organization is available if the internal appeal fails. Denial rates for SGLT2 inhibitors on appeal are not publicly tracked, but a 2021 JAMA Internal Medicine analysis found that external review reversal rates for specialty drugs exceeded 40% for plans with clear clinical guideline support [6].

How Generic Dapagliflozin Changes the Cost Picture

The FDA has approved generic dapagliflozin. Generic versions are bioequivalent to Farxiga and carry the same IRS prescription-drug eligibility for HSA and FSA accounts. Generic prices at launch are typically 80 to 85% below brand price, consistent with FDA's generic drug cost data. For a cash-pay patient, generic dapagliflozin at a Cost Plus or Costco pharmacy may represent a lower total cost than brand Farxiga even after applying a co-pay card, depending on the card's annual cap.

Prescribers can write "dapagliflozin" on the prescription with "substitution permitted" to enable automatic generic dispensing. Patients should confirm with their pharmacist that the generic is in stock, since supply can vary at launch.

Putting It All Together: A Decision Path for 2026

The right cost-reduction strategy depends on your insurance status.

Commercially insured: Use the AstraZeneca co-pay card first. Pay any residual with your HSA or FSA debit card. If the co-pay card covers the full cost, no HSA/FSA claim is needed.

Medicare Part D: You cannot use a manufacturer co-pay card. Use your existing HSA balance for cost-sharing until you reach the $2,000 annual out-of-pocket cap. After the cap, your cost is $0.

Uninsured or underinsured: Apply to AZ&Me for free drug. While waiting for approval, use a GoodRx coupon or purchase generic dapagliflozin through Cost Plus or a discount pharmacy. Pay with your HSA or FSA card and keep all receipts.

Generic available, cash-pay: Ask your prescriber to write for dapagliflozin generic. Compare prices at Cost Plus, Costco, and Amazon Pharmacy. All HSA/FSA eligible with a valid prescription receipt.

Per the ADA Standards of Care 2024, clinicians should proactively assess medication affordability at every visit and connect patients to cost-reduction resources, affordability directly predicts medication adherence, and dapagliflozin's cardiovascular and renal benefits only accrue with consistent long-term use [7].